Schoeneich M, Pécoud A R
Division of Allergy and Clinical Immunology, Chuv, Lausanne, Switzerland.
Clin Exp Allergy. 1990 Mar;20(2):171-4. doi: 10.1111/j.1365-2222.1990.tb02663.x.
Cetirizine is a new selective H1-antagonist. In a double-blind and placebo-controlled study, 11 subjects underwent a conjunctival provocation test (CPT) with a grass pollen extract to determine the effect of cetirizine on allergen-induced itching and redness of the eye. Results of CPTs were reproducible, as no difference was observed between the CPTs performed without any pre-treatment and the CPTs after placebo. Compared to placebo, cetirizine administered orally (10 mg twice a day for 4 days) and in double-blind fashion increased the conjunctival reaction threshold (P less than 0.004) by inhibiting both redness and itching of the eye. Cetirizine should protect patients against allergic conjunctivitis.
西替利嗪是一种新型选择性H1拮抗剂。在一项双盲、安慰剂对照研究中，11名受试者接受了草花粉提取物结膜激发试验（CPT），以确定西替利嗪对变应原诱发的眼部瘙痒和发红的影响。CPT结果具有可重复性，因为在未进行任何预处理的CPT与安慰剂后的CPT之间未观察到差异。与安慰剂相比，口服西替利嗪（每天两次，每次10毫克，共4天）并采用双盲方式，通过抑制眼部的发红和瘙痒，提高了结膜反应阈值（P<0.004）。西替利嗪应能保护患者免受过敏性结膜炎的侵害。
